Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00196599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseases Study sites: 0 to 1 · Publications: 2 to 3v2 Show all 3 changesShow less
    • Study sites: 0 to 1
    • Publications: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple combination with protease inhibitor is recommended. Such therapy induces side effects and the number of pills may reduce therapy adherence. The aim of this study is to evaluate the efficacy and the safety of a once daily FTC, ddI, efavirenz combination, in HIV patients with CD4 cell count over 100/mm3, antiretroviral naive.
Trial Details
NCT Number NCT00196599
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Triangle Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Dupont Applied Biosciences
Conditions HIV Infections, Antiretroviral Naive
Enrollment 39 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov